 BioVies NE3107 has now shown improvement of cognition and function on different Alzheimers rating scales, supported by biomarkers and neuroimaging data. The data just released from a Phase 2 placebo-controlled trial in Parkinsons disease with the same drug again shows strong efficacy, particularly in younger patients. 